Plain-English translation of NCT06291376 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , a medication given through an IV infusion, can help slow or stop kidney disease in people with IgA nephropathy (a condition where certain antibodies damage your kidneys). About 450 people will receive either the medication or a placebo every 8 weeks for roughly 2 years. Researchers want to see if this treatment protects kidney function better than current standard care alone.
IgA nephropathy can gradually damage the kidneys and lead to kidney failure, even with current treatments. This medication is designed to target a specific part of the immune system that contributes to kidney damage, so this trial aims to see if it can slow or prevent that progression.
You would visit the study clinic multiple times over about 2 years. At your first visit, you'll receive a loading dose of either the study medication or placebo through an IV, then receive maintenance doses every 8 weeks. Between visits, researchers will monitor your kidney function and urine protein levels to see how you're responding. After the main study ends at week 106, you'll have the option to continue receiving the active medication if it's available.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States